(dipivefrin hydrochloride ophthalmic solution, USP) 0.1%
PROPINE® contains dipivefrin hydrochloride in a sterile, isotonic solution. Dipivefrin HCI is a white, crystalline powder, freely soluble in water with an osmolality of approximately 250 - 330 mOsmol/kg.
PROPINE® (dipivefrin HCI ophthalmic solution, USP) is indicated as initial therapy for the control of intraocular pressure in chronic open-angle glaucoma. Patients responding inadequately to other antiglaucoma therapy may respond to addition of PROPINE®.
In controlled and open-label studies of glaucoma, Propine® ophthalmic solution demonstrated a statistically significant intraocular pressure-lowering effect. Patients using Propine® twice daily in studies with mean durations of 76-146 days experienced mean pressure reductions ranging from 20-24%.
Therapeutic response to Propine® ophthalmic solution twice daily is somewhat less than 2% epinephrine twice daily. Controlled studies showed statistically significant differences in lowering of intraocular pressure between Propine® and 2% epinephrine. In controlled studies in patients with a history of epinephrine intolerance, only 3% of patients treated with Propine® ophthalmic solution exhibited intolerance, while 55% of those treated with epinephrine again developed intolerance.
Therapeutic response to PROPINE® twice daily therapy is comparable to 2% pilocarpine 4 times daily. In controlled clinical studies comparing PROPINE® ophthalmic solution and 2% pilocarpine, there were no statistically significant differences in the maintenance of IOP levels for the two medications. PROPINE® does not produce miosis or accommodative spasm which cholinergic agents are known to produce. Night blindness often associated with miotic agents is not present with PROPINE® therapy. Patients with cataracts avoid the inability to see around lenticular opacities caused by constricted pupil.
Published Studies Related to Propine (Dipivefrin Ophthalmic)
[Changes in retinal blood flow by topical administration of 0.1% dipivefrin] [1999.11]
PURPOSE: Most of the antiglaucomatous drugs affect ocular blood flow. Blood flow of the anterior uvea under the effect of glaucoma medication has been described in the literature, but measurement of microcirculation at the posterior pole correlated to glaucoma medication is rarely found. We present a placebo-controlled study in which we focused on the short and long-term effects of topical dipivefrine 0.1% on the microcirculation of the retina and optic nerve head... CONCLUSION: Retinal capillary perfusion is affected by dipivefrine 0.1% medication. In neuroprotection, it is of interest that glaucoma medication did not alter the microcirculation in a way that leads to an increase of hypoxemia. Therefore, we consider dipivefrine 0.1% not to be useful for long-term glaucoma treatment.
Effects of dipivefrin and pilocarpine on pupil diameter, automated perimetry and LogMAR acuity. [1999.02]
BACKGROUND: A study was carried out to ascertain, in ophthalmologically normal subjects, the short-term effects of dipivefrin hydrochloride 0.1% on visual performance and make comparisons with pilocarpine... CONCLUSIONS: In normals dipivefrin causes mydriasis but does not affect the central visual field global indices (as assessed by STATPAC), or high- and low-contrast LogMAR acuity. Pilocarpine adversely affects the visual field and both measures of acuity. Knowledge of these effects is of value in glaucoma therapy and when monitoring the progression of visual loss.
Effects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability. [1998.04]
AIM: To investigate the effect on intraocular pressure (IOP) and aqueous flare of topical applications of latanoprost and dipivefrin alone or combined... CONCLUSIONS: Latanoprost and dipivefrin have an additive effect on IOP and no clinically significant effect on the permeability to proteins of the blood-aqueous barrier. This implies that the two drugs can be a useful combination for the treatment of glaucoma.
The efficacy of the combination of l-moprolol and dipivefrin in reducing the intraocular pressure in primary open-angle glaucoma or in ocular hypertension. [1994.11]
BACKGROUND: In this double-blind prospective trial the efficacy of lowering the intraocular pressure of l-moprolol given alone and in combination with dipivefrin was tested... CONCLUSION: This trial demonstrated that the combination of l-moprolol and dipivefrin is an effective and safe treatment for elevated intraocular pressure.
Dipivefrin reduces blood flow in the ciliary body in humans. [1994.04]
CONCLUSION: The observed data suggest that dipivefrin decreases ciliary body blood flow.
Clinical Trials Related to Propine (Dipivefrin Ophthalmic)
Safety and Efficacy of an Investigational Multi-Purpose Disinfecting Solution [Completed]
The purpose of this study is to determine if Alcon MPDS is safe and effective for silicone
hydrogel and soft hydrogel contact lens wearers.
Comparative Performance of a Bausch & Lomb Multipurpose Solution and Alcon OptiFree Replenish Multipurpose Solution [Completed]
To evaluate the product performance of a Bausch & Lomb Multipurpose solution when compared
to Alcon OptiFree Replenish Multipurpose Solution
Comparison of Functional Vision Provided by AMO Tecnis Z9000 and Alcon SA60AT Acrysof [Completed]
This study is to compare intraindividually the functional vision provided by two different
posterior chamber intraocular lenses: AMO Tecnis Z9000 and Alcon SA60AT Acrysoft. To see if
the aspherical intraocular lenses provide better functional vision than traditional
spherical intraocular lenses.
Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial [Completed]
The purpose of this study is to look at the outcomes of your vision after your cataract
surgery based on two different types of equipment that will be used during your surgery.
Evaluation of Alcon Ladarvision Wavefront-Guided PRK [Withdrawn]
The purpose of this study is to:
1. determine the safety of wavefront guided PRK
2. evaluate the efficacy of wavefront guided PRK
3. evaluate the differences in visual quality after treatment of wavefront guided PRK